Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination With Dostarlimab in Pediatric and Young Adult Participants With Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)

NCT06521567 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06521567
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06521567 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Dose Determination and Dose Expansion Study of Cobolimab in Combination With Dostarlimab in Pediatric and Young Adult Participants With Newly Diagnosed and Relapsed/Refractory Tumors (POPSTAR)
Lead sponsor
GlaxoSmithKline
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
March 6, 2025
Completion date
October 13, 2026
Enrollment
83 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse intrinsic pontine glioma (dipg), ependymoma, fibrolamellar carcinoma, glioblastoma multiforme (gbm), hepatic tumors, hepatoblastoma, hepatocellular carcinoma (hcc), high and low grade glioma, hodgkin lymphoma, melanoma, osteosarcoma, rhabdomyosarcoma